Related Experiment Video
Updated: Jul 1, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal
Liuqing Yang1, Ye Yang1, Jing Zhang1
1Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, 100191, Beijing, China.
Abstract:
PROteolysis TArgeting Chimeras (PROTACs) have been considered the next blockbuster therapies. However, due to their inherent limitations, the efficacy of PROTACs is frequently impaired by limited tissue penetration and particularly insufficient cellular internalization into their action sites. Herein, based on the ultra-pH-sensitive and enzyme-sensitive nanotechnology, a type of polymer PROTAC conjugated and pH/cathepsin B sequential responsive nanoparticles (PSRNs) are deliberately designed, following the construction of the PROTAC for Cyclin-dependent kinase 4 and 6 (CDK4/6). Colorectal cancer (CRC) which hardly responds to many treatments even immune checkpoint blockades was selected as the tumor model in this study. As a result, PSRNs were found to maintain nanostructure (40 nm) in circulation and efficiently accumulated in tumors via enhanced permeation and retention effect. Then, they were dissociated into unimers (<10 nm) in response to an acidic tumor microenvironment, facilitating tumor penetration and cellular internalization. Eventually, the CDK4/6 degrading PROTACs were released intracellularly following the cleavage of cathepsin B. Importantly, PSRNs led to the enhanced degradation of target protein in vitro and in vivo. The degradation of CDK4/6 also augmented the efficacy of immune checkpoint blockades, through the upregulation of programmed cell death-ligand 1 (PD-L1) expression in cancer cells and the suppression of regulatory T cells cell proliferation in tumor microenvironment. By combination with α-PD-1, an enhanced anti-tumor outcome is well achieved in CT26 tumor model. Overall, our study verifies the significance of precise intracellular delivery of PROTACs and introduces a promising therapeutic strategy for the targeted combination treatment of CRC.
Insights
Polymer nanoparticles enhance PROTAC delivery for colorectal cancer therapy. These nanoparticles improve tumor penetration and cellular uptake, leading to effective protein degradation and synergistic anti-cancer effects when combined with immune checkpoint inhibitors.
Area of Science:
- Biotechnology
- Nanomedicine
- Oncology
Background:
- PROteolysis TArgeting Chimeras (PROTACs) show therapeutic promise but face challenges in tissue penetration and cellular internalization.
- Colorectal cancer (CRC) is often resistant to conventional treatments, including immune checkpoint blockades.
Purpose of the Study:
- To design pH/cathepsin B sequential responsive nanoparticles (PSRNs) for enhanced intracellular delivery of PROTACs targeting Cyclin-dependent kinase 4 and 6 (CDK4/6).
- To evaluate the efficacy of PSRNs in a colorectal cancer model and their combination with immune checkpoint inhibitors.
Main Methods:
- Development of polymer PROTAC-conjugated nanoparticles (PSRNs) with pH and enzyme sensitivity.
- In vitro and in vivo evaluation of nanoparticle accumulation, penetration, cellular uptake, and PROTAC release in a colorectal cancer model.
- Assessment of CDK4/6 degradation, PD-L1 expression, regulatory T cell proliferation, and anti-tumor efficacy in combination with α-PD-1 therapy.
Main Results:
- PSRNs (40 nm) accumulated in tumors and dissociated into unimers (<10 nm) in the acidic tumor microenvironment, enhancing penetration and cellular uptake.
- Intracellular release of CDK4/6-degrading PROTACs was triggered by cathepsin B cleavage, leading to enhanced target protein degradation in vitro and in vivo.
- Combination therapy with α-PD-1 significantly improved anti-tumor outcomes in the CT26 tumor model, associated with PD-L1 upregulation and suppressed regulatory T cell proliferation.
Conclusions:
- Precise intracellular delivery of PROTACs is crucial for enhancing therapeutic efficacy.
- PSRNs offer a promising strategy for targeted combination therapy in colorectal cancer by improving PROTAC delivery and augmenting immune checkpoint blockade efficacy.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Rate-Programmed II
Modified-Release Drug Delivery Systems: Rate-Programmed I
Modified-Release Drug Delivery Systems: Site-Targeted
Site-Targeted Drug Delivery Systems: Polymeric Carriers

